Back To: Home

CLICK HERE FOR WHAT'S NEW IN:
 




 

Rosetta sells Parkway Clinical Labs, reports drop in Q1 losses
June 2009
SHARING OPTIONS:

REHOVOT, Israel—Choosing to focus exclusively on the development of a colon cancer screening test, Rosetta Genomics in May sold its Parkway Clinical Laboratories business for $2.5 million—taking a hit, as the miRNA diagnostics maker purchased the laboratory for $2.9 million last July. Rosetta said Parkway's drug abuse and pre-employment drug testing businesses do not fit within its focus on developing cancer diagnostic tests. Rosetta reported revenues of $654,000 for the first quarter of 2009, most of which was from selling Parkway. Rosetta reported a quarterly operating loss of $3.7 million, unchanged from 2008. R&D spending was $1.7 million for the first quarter, down from $2.4 million in the first quarter of 2008. Rosetta lost $3.3 million, or 27 cents per share, compared with a $3.4 million loss in the same period of 2008.

 

Back



PAGE UTILITIES


CONTACT US
DDNEWS
Published by Old River Publications LLC
19035 Old Detroit Road
Rocky River, OH USA 44116
Ph: 440-331-6600  |  Fax: 440-331-7563
 
© Copyright 2020 Old River Publications LLC. All righs reserved.  |  Web site managed and designed by OffWhite.